

DESCRIPTION

Species Reactivity	Human/Mouse/Rat
Specificity	Detects human, mouse, and rat FKBP12.6 in Western blots. In Western blots, approximately 15% cross-reactivity with recombinant human FKBP12 and less than 1% cross-reactivity with recombinant human FKBP13 and FKBP25 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human FKBP12.6 Met1-Glu108 Accession # P68106
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

FK506 binding protein, 12.6 kDa molecular weight (FKBP12.6), also called FKBP1B, is a peptidyl-prolyl isomerase that catalyzes the transition between *cis*- and *trans*- proline residues critical for proper folding of proteins. The immunosuppressant FK506 is a potent inhibitor of FKBP12.6. FKBP12.6 is localized in the sarcoplasmic reticulum associated with the Ryanodine receptor RYR2. PKA-induced phosphorylation of RYR2 causes FKBP12.6 dissociation. In heart failure, RYR2 is hyperphosphorylated and has low levels of FKBP12.6 bound to it. Male FKBP12.6 knockout mice have cardiac hypertrophy and lethal exercise arrhythmias.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.